Trial Profile
A randomised double blind phase 2 trial of whole brain radiotherapy with or without vandetanib in metastatic melanoma with brain metastases
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs Vandetanib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- Acronyms RADVAN
- 06 Oct 2016 Primary endpoint (Efficacy of vandetanib in combination with radiotherapy, compared with radiotherapy; Timepoint(s): Progression free survival in brain (as assessed by MRI scan))has not been met, according to results published in the British Journal of Cancer.
- 06 Oct 2016 Results published in the British Journal of Cancer
- 12 Sep 2014 Accrual to date is 27% according to United Kingdom Clinical Research Network